Sign In
Buy AMRX
$12.88
+0.225 (+1.78%)
At Close: Jun 03, 2026
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript
12:26pm, Friday, 01'st Mar 2024
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say
10:31am, Friday, 01'st Mar 2024
The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
08:16am, Friday, 01'st Mar 2024
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.23 per share a year ago.
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
06:00am, Friday, 01'st Mar 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31,
Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
10:16am, Tuesday, 27'th Feb 2024
Beyond analysts' top -and-bottom-line estimates for Amneal (AMRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Amneal (AMRX) Shows Fast-paced Momentum But Is Still a Bargain Stock
09:51am, Wednesday, 21'st Feb 2024
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed t
Amneal to Participate at Upcoming Investor Conference
08:00am, Tuesday, 13'th Feb 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference. Ba
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
04:05pm, Thursday, 08'th Feb 2024
BRIDGEWATER, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmissi
The Jobs Report Blows Away Forecasts
09:26pm, Friday, 02'nd Feb 2024
January's payrolls report shows 353,000 jobs
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
04:05pm, Wednesday, 31'st Jan 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its fourth quarter and full year 2023 financial results on Friday, March 1
GSK, Amneal, Kaléo delist patents from FDA's orange book
12:15pm, Friday, 22'nd Dec 2023
Pharmaceutical companies, GSK (GSK), Amneal Pharmaceuticals (AMRX) and Kaléo have agreed to delist some of their patents from the FDA's orange book. GSK withdrew four inhaler patents and Amneal withd
Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
10:23pm, Saturday, 09'th Dec 2023
Amneal Pharmaceuticals' stock price has been on a strong bull run, now exceeding $5 per share and up over >145% this year. The company experienced losses in 2018 and 2019 but has since seen improvemen
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript
03:19pm, Tuesday, 07'th Nov 2023
Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Anthony DiMeo - Head-Investor Relations Chirag Patel - Co-Founder & Co-Chief
Amneal (AMRX) Upgraded to Buy: Here's Why
01:32pm, Wednesday, 25'th Oct 2023
Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
11:22am, Wednesday, 25'th Oct 2023
Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
